Amol Akhade: Puxitatug samrotecan probably looks most promising among the new ADC data coming up from ESMO 24

Amol Akhade shared a post on LinkedIn:

“What’s the new ADC data coming up from ESMO 24 ?
Puxitatug samrotecan ( anti -B7-H4 ADC ) probably looks most promising .
Rinatabart Sesutecan already has FDA fast track Designation ( FR-alpha ADC )

New Claudin6 and Claudin 18.2 ADC, Anti Her2 ADC and Trop 2 ADC data needs to be watched .
whats your pick ?”

Source: Amol Akhade/LinkedIn

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.